Evaluation in alcohol use disorders – insights from the nalmefene experience
Nalmefene was the first treatment approved by the European Medicines Agency for reducing alcohol consumption in adult patients with alcohol dependence. It is often presented as a paradigm shift in therapeutics, but major issues limit the interpretation of the evidence supporting its use. The randomised trials submitted provided no evidence of harm reduction, the differences on consumption outcomes were of questionable clinical relevance, the target population was defined a posteriori and the drug was compared to a placebo although naltrexone was already used off-label. No post-approval randomised study is currently designed to clearly address these issues. In addition, nalmefene trials have been uncritically cited, even in guidelines. This experience reveals weaknesses in drug evaluations in alcohol dependence, which call for changes. We propose to dispense with alcohol consumption as a surrogate outcome, to consider comparative effectiveness issues, and to recommend randomised post-approval studies in case of controversial approval.
On 13 December 2012, nalmefene, an opioid antagonist, was approved by the European Medicines Agency (EMA) for the reduction of alcohol consumption in adult patients with alcohol dependence, a high drinking-risk level, no physical withdrawal symptoms and not requiring immediate detoxification. It is the first treatment in this indication when the usual aim in alcohol dependence is abstinence from drinking. The approval [1] was based on the results of two phase III randomised controlled trials (RCTs) lasting 6 months [2, 3], one lasting 1 year [4], and four earlier RCTs including dose–response studies (two of these were unpublished studies) [5, 6]. Some additional supporting evidence was also presented, including pooled subgroup analyses [7] and further analyses on the expected harm reduction (alcohol-related physical health outcomes, injuries or social consequences) based on the literature data and on modelling from the clinical trial data [8, 9]. Despite this body of evidence, the approval was contested, with some disagreement between and within the different health authorities. For instance, six members of the Committee for Medicinal Products for Human Use at the EMA expressed divergent positions in an appendix to the assessment report. The National Institute for Care and Excellence (NICE) in the UK initially recommended nalmefene as a possible treatment for alcohol dependence [10] but subsequently distanced itself from this earlier advice [11]. The German and Swedish health authorities simply stated that there was no added benefit from nalmefene [12, 13].
The RCTs performed have thus failed to demonstrate an unequivocal benefit for the drug, despite the fact that, from a regulatory perspective, this should be their principal aim.
We propose here to examine the evidence that led to the approval of nalmefene and to understand why studies were not unequivocal in this specific case, how their results were integrated into the health authority decisions and how the controversy spread in the medical literature. Our final purpose is to propose relevant changes concerning therapeutic evaluation in the field of alcohol dependence.
Autoři:
Florian Naudet 1*; Clément Palpacuer 2; Rémy Boussageon 3; Bruno Laviolle 2
Působiště autorů:
Meta-Research Innovation Center at Stanford (METRICS), Stanford University, 1070 Arastradero Road, Palo Alto, CA 94304, USA.
1; INSERM Centre d’Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France. 3Département de Médecine Générale, Faculté de Médecine de Poitiers, Poitiers, France.
2
Vyšlo v časopise:
BMC Medicine 2016, 14:119
Kategorie:
Correspondence
prolekare.web.journal.doi_sk:
https://doi.org/10.1186/s12916-016-0664-9
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0664-9
Souhrn
Nalmefene was the first treatment approved by the European Medicines Agency for reducing alcohol consumption in adult patients with alcohol dependence. It is often presented as a paradigm shift in therapeutics, but major issues limit the interpretation of the evidence supporting its use. The randomised trials submitted provided no evidence of harm reduction, the differences on consumption outcomes were of questionable clinical relevance, the target population was defined a posteriori and the drug was compared to a placebo although naltrexone was already used off-label. No post-approval randomised study is currently designed to clearly address these issues. In addition, nalmefene trials have been uncritically cited, even in guidelines. This experience reveals weaknesses in drug evaluations in alcohol dependence, which call for changes. We propose to dispense with alcohol consumption as a surrogate outcome, to consider comparative effectiveness issues, and to recommend randomised post-approval studies in case of controversial approval.
On 13 December 2012, nalmefene, an opioid antagonist, was approved by the European Medicines Agency (EMA) for the reduction of alcohol consumption in adult patients with alcohol dependence, a high drinking-risk level, no physical withdrawal symptoms and not requiring immediate detoxification. It is the first treatment in this indication when the usual aim in alcohol dependence is abstinence from drinking. The approval [1] was based on the results of two phase III randomised controlled trials (RCTs) lasting 6 months [2, 3], one lasting 1 year [4], and four earlier RCTs including dose–response studies (two of these were unpublished studies) [5, 6]. Some additional supporting evidence was also presented, including pooled subgroup analyses [7] and further analyses on the expected harm reduction (alcohol-related physical health outcomes, injuries or social consequences) based on the literature data and on modelling from the clinical trial data [8, 9]. Despite this body of evidence, the approval was contested, with some disagreement between and within the different health authorities. For instance, six members of the Committee for Medicinal Products for Human Use at the EMA expressed divergent positions in an appendix to the assessment report. The National Institute for Care and Excellence (NICE) in the UK initially recommended nalmefene as a possible treatment for alcohol dependence [10] but subsequently distanced itself from this earlier advice [11]. The German and Swedish health authorities simply stated that there was no added benefit from nalmefene [12, 13].
The RCTs performed have thus failed to demonstrate an unequivocal benefit for the drug, despite the fact that, from a regulatory perspective, this should be their principal aim.
We propose here to examine the evidence that led to the approval of nalmefene and to understand why studies were not unequivocal in this specific case, how their results were integrated into the health authority decisions and how the controversy spread in the medical literature. Our final purpose is to propose relevant changes concerning therapeutic evaluation in the field of alcohol dependence.
Zdroje
1. European Medicines Agency. Assessment report: Selincro—international non-proprietory name: nalmefene. EMA/78844/2013. 2012. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002583/WC500140326.pdf. Accessed 16 Nov 2015.
2. Gual A, He Y, Torup L, van den Brink W, Mann K. A randomised, doubleblind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–42.
3. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–13.
4. van den Brink W, Sorensen P, Torup L, Mann K, Gual A. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28(8):733–44.
5. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Makela R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebocontrolled multicenter study. Alcohol Clin Exp Res. 2007;31(7):1179–87.
6. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421–8.
7. van den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013;48(5):570–8.
8. Laramee P, Brodtkorb TH, Rahhali N, Knight C, Barbosa C, Francois C, Toumi M, Daeppen JB, Rehm J. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014;4(9):e005376.
9. Roerecke M, Sorensen P, Laramee P, Rahhali N, Rehm J. Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk. J Psychopharmacol. 2015;29(11):1152–8. doi:10.1177/0269881115602487. Epub 2015 Sep 8.
10. National Institute for Health and Care Excellence. Nalmefene for reducing alcohol consumption in people with alcohol dependence: evaluation report. London: National Institute for Health and Care Excellence; 2014. https://www.nice.org.uk/guidance/ta325?unlid=3629887952016628192516.
11. Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan
MY. Nalmefene for reducing alcohol consumption in people with alcohol
dependence: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2015;33(8):833–47.
12. Tandvårds-och Läkemedelsförmånsverket. Selincro ingår inte ihögkostnadsskyddet. 2015. Available: http://www.tlv.se/beslut/beslutlakemedel/avslag-uteslutningar/Selincro-ingar-inte-i-hogkostnadsskyddet. Accessed 16 Nov 2015.
13. Stafford N. German evaluation says new drug for alcohol dependence is no better than old one. BMJ. 2014;349:g7544.
14. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.
15. Muckle W, Muckle J, Welch V, Tugwell P. Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. Cochrane Database Syst Rev. 2012;12:CD006747.
16. Roerecke M, Gual A, Rehm J. Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and metaanalyses. J Clin Psychiatry. 2013;74(12):e1181–9.
17. Laramee P, Leonard S, Buchanan-Hughes A, Warnakula S, Daeppen JB, Rehm J. Risk of all-cause mortality in alcohol-dependent individuals: a systematic literature review and meta-analysis. EBioMedicine. 2015;2(10):1394–404.
18. Rehm J, Roerecke M. Reduction of drinking in problem drinkers and allcause mortality. Alcohol Alcohol. 2013;48(4):509–13.
19. Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction. 2016;111(8): 1477–87. doi:10.1111/add.13438. Epub 2016 Jun 5.
20. Witkiewitz K, Falk DE, Kranzler HR, Litten RZ, Hallgren KA, O’Malley SS, Anton RF. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014;38(11):2826–34.
21. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz D, Diaz-Granados N, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553.
22. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA. 2014;311(4):405–11.
23. Naudet F, Granger B, Braillon A. Cost-effectiveness of nalmefene: exaggerated expectations or fallacy? Alcohol Alcohol. 2016;3. [Epub ahead of print]
24. 1ère séance: Questions au Gouvernement (26 février 2014). 2014. <>http://www.assemblee-nationale.fr/14/cri/2013-2014/20140182.asp.
25. Francois C, Rahhali N, Chalem Y, Sorensen P, Luquiens A, Aubin HJ. The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcoholdependent patients. PLoS One. 2015;10(6):e0129289.
26. Brodtkorb TH, Bell M, Irving AH, Laramee P. The cost effectiveness of nalmefene for reduction of alcohol consumption in alcohol-dependent patients with high or very high drinking-risk levels from a UK societal perspective. CNS Drugs. 2016;30(2):163–77.
27. Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016;51(3): 283–90.
28. France CP, Gerak LR. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther. 1994;270(3):992–9.
29. Swift RM. Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry. 2013;73(8):700–1.
30. Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920–30.
31. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091–7.
32. Soyka M, Friede M, Schnitker J. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? results from an indirect meta-analysis. Pharmacopsychiatry. 2016;49(2):66–75. doi:10.1055/s-0035-1565184. Epub 2016 Feb 4.
33. Naudet F. Comparing nalmefene and naltrexone in alcohol dependence: is there a spin? Pharmacopsychiatry. 2016;7. [Epub ahead of print]
34. Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619–26.
35. Soyka M, Mutschler J. Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine. Prog Neuropsychopharmacol Biol Psychiatry. 2016;3(70):148–61. doi:10.1016/j.pnpbp.2015.11.003. Epub 2015 Nov 12.
36. Marazziti D, Presta S, Baroni S, Mungai F, Piccinni A, Mucci F, Dell’Osso L. Nalmefene: a novel drug for an old disorder. Curr Med Chem. 2015; 22(27):3162–8.
37. Serecigni JG. Opioid receptor antagonists in the treatment of alcoholism. Adicciones. 2015;27(3):214–30.
38. Luquiens A, Aubin HJ. Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. Patient Prefer Adherence. 2014;8:1347–52.
39. Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(1):25–37.
40. Braillon A. Recommendations of French Alcohol Society and European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(6):535–6. doi:10.1111/cns.12556. Epub 2016 May 3. No abstract available
41. Ugochukwu C, Bagot KS, Delaloye S, Pi S, Vien L, Garvey T, Bolotaulo NI, Kumar N, Ishak WW. The importance of quality of life in patients with alcohol abuse and dependence. Harv Rev Psychiatry. 2013;21(1):1–17.
42. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and metaanalysis. JAMA. 2014;311(18):1889–900.
43. Ioannidis JP. Mega-trials for blockbusters. JAMA. 2013;309(3):239–40.
44. Garattini S. The European Medicines Agency is still too close to industry. BMJ. 2016;353:i2412.
45. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebocontrolled trial. Am J Psychiatry. 1999 Nov;156(11):1758-64.
46. Balldin J, Berglund M, Borg S, Månsson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003 Jul; 27(7):1142-9.
47. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug;25(4):349-57.
48. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000 May;22(5):493-503.
49. O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and nonnatives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res. 2008 Jul;32(7):1271-83. doi:10.1111/j.1530-0277.2008.00682.x.
Článok vyšiel v časopise
BMC Medicine
2016 Číslo 119
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle